KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Intangibles (2017 - 2024)

Historic Intangibles for Aquestive Therapeutics (AQST) over the last 8 years, with Q1 2024 value amounting to $1.2 million.

  • Aquestive Therapeutics' Intangibles fell 1124.64% to $1.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.2 million, marking a year-over-year decrease of 1124.64%. This contributed to the annual value of $1.3 million for FY2023, which is 1094.08% down from last year.
  • Aquestive Therapeutics' Intangibles amounted to $1.2 million in Q1 2024, which was down 1124.64% from $1.3 million recorded in Q4 2023.
  • Aquestive Therapeutics' 5-year Intangibles high stood at $7.4 million for Q2 2020, and its period low was $25000.0 during Q2 2022.
  • Its 5-year average for Intangibles is $1.6 million, with a median of $1.3 million in 2023.
  • In the last 5 years, Aquestive Therapeutics' Intangibles tumbled by 9913.54% in 2021 and then soared by 532800.0% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Intangibles (Quarter) stood at $102000.0 in 2020, then tumbled by 50.0% to $51000.0 in 2021, then soared by 2713.73% to $1.4 million in 2022, then fell by 10.94% to $1.3 million in 2023, then dropped by 3.05% to $1.2 million in 2024.
  • Its Intangibles stands at $1.2 million for Q1 2024, versus $1.3 million for Q4 2023 and $1.3 million for Q3 2023.